Table 1.
Patient characteristics
| 1 Biopsy | 2 Biopsies | 3–8 Biopsies | p Value | ||||
|---|---|---|---|---|---|---|---|
| Median age, (IQR) | 62 | (58–67) | 63 | (59–67) | 63 | (60–68) | 0.017* |
| No. Caucasian (%) | 1,354 | (60) | 207 | (57) | 60 | (49) | 0.027† |
| Median kg/m2 body mass index (IQR) | 28 | (25–31) | 28 | (25–31) | 28 | (26–30) | 0.979* |
| Median ng/ml baseline PSA (IQR) | 6.3 | (4.6–10.0) | 7.7 | (5.2–11.2) | 8.1 | (6.2–12.8) | <0.001* |
| Median yr of surgery (IQR) | 2002 | (1996–2006) | 2002 | (1997–2005) | 2002 | (1998–2006) | 0.316* |
| Median biopsy cores obtained (IQR) | 8 | (6–11) | 8 | (6–12) | 10 | (8–12) | 0.001* |
| No. clinical stage (%): | 0.002† | ||||||
| T1 | 1,107 | (60) | 218 | (66) | 81 | (75) | |
| T2 or Greater | 729 | (40) | 111 | (34) | 27 | (25) | |
| No. biopsy Gleason sum (%): | 0.010† | ||||||
| 2–6 | 1,333 | (61) | 247 | (68) | 85 | (70) | |
| 7 | 653 | (30) | 80 | (22) | 31 | (25) | |
| 8–10 | 201 | (9) | 34 | (9) | 6 | (5) | |
| No. pathological stage (%): | 0.017† | ||||||
| T0 | 1 | (less than 1) | 0 | 1 | (1) | ||
| T2 | 1,548 | (72) | 260 | (76) | 98 | (82) | |
| T3–4 | 596 | (28) | 83 | (24) | 21 | (18) | |
| No. postop Gleason sum (%): | 0.095† | ||||||
| 2–6 | 908 | (41) | 160 | (44) | 58 | (48) | |
| 7 | 1,045 | (47) | 164 | (46) | 54 | (45) | |
| 8–10 | 262 | (12) | 36 | (10) | 9 | (7) | |
| No. pos surgical margin (%) | 934 | (42) | 152 | (43) | 41 | (34) | 0.148† |
| Median gm prostate wt (IQR) | 38 | (30–50) | 43 | (32–56) | 50 | (39–69) | <0.001* |
*
Kruskal-Wallis test.
†
Chi-square test.